- Email: [email protected]
The efficacity control of D-Trp6-LHRH in prostate cancers by trans-rectal ultrasonography
1387
A45 usE 0F m mm AGONIST (LHBH,) IN THE TREATMENT 0F MALES WITH CENTRAL PRECOCIOUS PUBERTY (CPP). D. Beardsworth, M. Wierman*, J. Mansfield, J. Crawford, J. Crigler, H. Bode, D. Kushner and W. Crowley, Dept Gyn, Med and Ped, Vincent Labs, Mass. General Hosp, Children's Hosp, Boston, MA 02114. LHRH, suppresses gonadarche in girls with CPP, but little information is available regarding the response of males to this therapy. Four boys with CPP received LHRHa for 12 consecutive months. Prior to therapy, the patients had Tanner stage II-IV pubertal development, a mean testicular volume of 16f3 (SE) ml, a chronologic age of 7.7f0.6 years and a bone age of '2.9kO.4 years. Followrnq therapy, 3/4 boys demonstrated regression of secondary sex characteristics and all had a marked decrease in testicular size to 7?rl ml. Bone age advanced 4.520.5 months during 12 months of exposure to LHRH,. The pretreatment pubertal growth velocity of 13.5k2.7 cm/yr fell significantly to 5.5i.13 cm/yr over the year of therapy. Predicted height was increased 3.84f2.24 cm. Endocrinoloqic parameters are summarized below: T1 LH2 ALH3 FSH2 &?SH3 503+103 !.61+.07 5.04k.49 3.32f14 2.00f.58 Pre-Rx Post 1 year 19f4 1.06f.02 1.29+.06 0.222.12 0.05r.07 Significance PC.001 PC.01 PC.001 pi.05 PC.01 l=plasma testosterone (ng%) in a PM pool; 2=mean of 8h pulsation study (mIU/ml LER 907); 3=AFSH or !!,LHafter LHRH (2.5 mcq/kg SC). In boys with CPP, LHRH, is capable of: 1) reversing the clinical features of precocity, 2) abolishing the pulsatile release of qonadotropins withsubsequent suppression of testosterone production,and 3) retarding skeletal maturation, slowing growth velocity, and improving predicted adult stature.
A46 THE EFFICACITY CONTROL OF D-Trp6-LHRH IN PROSTATE CANCERS BY TRANS-RECTAL ULTRASONOGRAPHY. H. Botto*, F. Richard and M. Camey CMC Foch, 40 rue Worth, 92151 Suresnes, France, and F. Mathieu, Instjtut Curie, rue d'Ulm, 75005 Paris, France. We have presented here the first controls made by trans-rectal ultrasonography of the efficacity of D-Trp6-LHRH on the prostate cancers. This new method permii;s the approximation of the volume, of the capsule and the nodular prostate structure far superior to the classic pubis ultrasonograpk Our study is aimed in the prostate cancers found in stage C and in stage D. Controlled study was made on the D-Trp6-LHRH versus castration. The transrectal ultrasonography in the patients under D-Trp6-LHRH showed a constant reduction and an important stability in the prostate volume. On the contrary, the trans-rectal ultrasonography in the castrated patient showed a variable reduction &nci an inconstant prostatic volume. A series of illustrated pictures are presented here coverine tb<-_ su'dject.
A45 usE 0F m mm AGONIST (LHBH,) IN THE TREATMENT 0F MALES WITH CENTRAL PRECOCIOUS PUBERTY (CPP). D. Beardsworth, M. Wierman*, J. Mansfield, J. Crawford, J. Crigler, H. Bode, D. Kushner and W. Crowley, Dept Gyn, Med and Ped, Vincent Labs, Mass. General Hosp, Children's Hosp, Boston, MA 02114. LHRH, suppresses gonadarche in girls with CPP, but little information is available regarding the response of males to this therapy. Four boys with CPP received LHRHa for 12 consecutive months. Prior to therapy, the patients had Tanner stage II-IV pubertal development, a mean testicular volume of 16f3 (SE) ml, a chronologic age of 7.7f0.6 years and a bone age of '2.9kO.4 years. Followrnq therapy, 3/4 boys demonstrated regression of secondary sex characteristics and all had a marked decrease in testicular size to 7?rl ml. Bone age advanced 4.520.5 months during 12 months of exposure to LHRH,. The pretreatment pubertal growth velocity of 13.5k2.7 cm/yr fell significantly to 5.5i.13 cm/yr over the year of therapy. Predicted height was increased 3.84f2.24 cm. Endocrinoloqic parameters are summarized below: T1 LH2 ALH3 FSH2 &?SH3 503+103 !.61+.07 5.04k.49 3.32f14 2.00f.58 Pre-Rx Post 1 year 19f4 1.06f.02 1.29+.06 0.222.12 0.05r.07 Significance PC.001 PC.01 PC.001 pi.05 PC.01 l=plasma testosterone (ng%) in a PM pool; 2=mean of 8h pulsation study (mIU/ml LER 907); 3=AFSH or !!,LHafter LHRH (2.5 mcq/kg SC). In boys with CPP, LHRH, is capable of: 1) reversing the clinical features of precocity, 2) abolishing the pulsatile release of qonadotropins withsubsequent suppression of testosterone production,and 3) retarding skeletal maturation, slowing growth velocity, and improving predicted adult stature.
A46 THE EFFICACITY CONTROL OF D-Trp6-LHRH IN PROSTATE CANCERS BY TRANS-RECTAL ULTRASONOGRAPHY. H. Botto*, F. Richard and M. Camey CMC Foch, 40 rue Worth, 92151 Suresnes, France, and F. Mathieu, Instjtut Curie, rue d'Ulm, 75005 Paris, France. We have presented here the first controls made by trans-rectal ultrasonography of the efficacity of D-Trp6-LHRH on the prostate cancers. This new method permii;s the approximation of the volume, of the capsule and the nodular prostate structure far superior to the classic pubis ultrasonograpk Our study is aimed in the prostate cancers found in stage C and in stage D. Controlled study was made on the D-Trp6-LHRH versus castration. The transrectal ultrasonography in the patients under D-Trp6-LHRH showed a constant reduction and an important stability in the prostate volume. On the contrary, the trans-rectal ultrasonography in the castrated patient showed a variable reduction &nci an inconstant prostatic volume. A series of illustrated pictures are presented here coverine tb<-_ su'dject.